The Department of Defense awarded Philips (NYSE: PHG ) Healthcare Informatics an $88.5 million-ceiling value, firm-fixed-price contract for the supply of a digital imaging network-picture archive�system. In so doing, it made progress on a project that's been in the works for 16 years.
In 1997, the DoD first issued requirements for what was then designated the "Digital Imaging Network-Picture Archiving and Communications System." At the time, DIN-PACS was described as "an open systems network of digital devices designed for the effective acquisition, transmission, display and management of diagnostic imaging studies." In essence, it would digitize X-Ray and MRI scans and put them in a form that could be easily transmitted from doctor-to-doctor electronically. DIN-PACS would be made interoperable with not just civilian hospitals in the U.S., but designed based on two truly international standards, Digital Imaging and Communications in Medicine (DICOM) and Health Level 7 (HL7).
Top Freight Companies For 2016: Roper Industries Inc.(ROP)
Roper Industries, Inc. designs, manufactures, and distributes radio frequency (RF) products and services, industrial technology products, energy systems and controls, and medical and scientific imaging products and software. Its Medical and Scientific Imaging segment offers patient positioning devices, 3-D measurement technology, diagnostic and therapeutic disposable products, ultrasound bladder volume measurement instruments, and video laryngoscopes; digital imaging products and software; and handheld and vehicle mount computers and software. The company?s Energy Systems and Controls segment produces control systems, fluid properties testing equipment, industrial valves and controls, sensors and controls, and non-destructive inspection and measurement products and solutions. Its Industrial Technology segment produces water and fluid handling pumps, equipment and consumables, leak testing equipment, flow measurement and metering equipment, water meter, and automatic meter reading products and systems. The company?s RF Technology segment provides radio frequency identification communication technology and software solutions that are used in toll and traffic systems and processing; security and access control; campus card systems; software-as-a-service in the freight matching and food industries; and metering and remote monitoring applications. It markets its products to RF applications, medical, water, energy, research, education, software-as-a-service-based information networks, and security markets. The company distributes its products through direct sales personnel, manufacturers? representatives, value added resellers, original equipment manufacturers, and distributors. It principally operates in the United States, Canada, Asia, Europe, the Middle East, and South America. Roper Industries, Inc. was founded in 1981 and is based in Sarasota, Florida.
Advisors' Opinion:- [By Rich Duprey]
It's a bit incongruous, but industrial manufacturing specialist Roper� (NYSE: ROP ) is now the proud owner of Managed Health Care Associates, a New Jersey-based supplier of services for�alternate site health-care providers.�The transaction was valued at approximately $1 billion, and was funded from Roper's�available cash and borrowings under its credit facility.
- [By Marc Bastow]
Radio frequency products manufacturer and distributor Roper (ROP) raised its quarterly dividend 21% to 20 cents per share, payable on Jan. 14 to shareholders of record as of Jan. 10. This marks the 21st consecutive rise in Roper’s annual dividend.
ROP Dividend Yield: 0.6% - [By Lauren Pollock]
Among the companies with shares expected to actively trade in Monday’s session are Merck(MRK) & Co., Biogen Idec Inc.(BIIB) and Roper Industries Inc.(ROP)
Top 10 International Stocks To Invest In 2015: Lightstream Resources Ltd (LSTMF.PK)
Lightstream Resources Ltd, formerly PetroBakken Energy Ltd., is a Canada-based oil and gas exploration and production company. The Company�� principal operating areas include southeastern Saskatchewan where it targets the Bakken formation and conventional Mississippian reservoirs, central Alberta, where it is focused on the Cardium formation, and north-central Alberta, where it is engaged in exploring for light oil resource plays. In addition, the Company also has land holdings in the Horn River and Montney plays in northeast British Columbia. On December 31, 2012, Petrobank Energy and Resources Ltd. and PetroBakken Energy Ltd. announced the completion of the reorganization. The Reorganization resulted in a newly incorporated company PetroBakken Energy Ltd. (New PetroBakken). Advisors' Opinion:- [By MLP Trader]
Here are the current top five companies in the list:
CompanySymbolEV/BOEPD/NetbackPrice/NAVEV/DACFPinecrest(PNCGF.PK)53564%4.0XLightstream(LSTMF.PK)131753%4.5XNovus(NOVUF.PK)133290%4.1XZargon(ZARFF.PK)138664%5.6XTwin Butte(TBTEF.PK)155885%5.5XOf the larger companies, one that remains obstinately near the top of the list is Lightstream . Lightstream trades at 40% of its book value and a whopping 13.4% yield.
Top 10 International Stocks To Invest In 2015: Micron Technology Inc.(MU)
Micron Technology, Inc., together with its subsidiaries, engages in the manufacture and marketing of semiconductor devices worldwide. Its products include dynamic random access memory (DRAM) products that provide data storage and retrieval, which include DDR2 and DDR3; and other specialty DRAM memory products, including DDR, SDRAM, DDR and DDR2 mobile low power DRAM, pseudo-static RAM, and reduced latency DRAM. The company also offers NAND flash memory products, which are electrically re-writeable and non-volatile semiconductor devices that retain content when power is turned off. In addition, it provides NOR flash memory products that are electrically re-writeable and non-volatile semiconductor memory devices; phase change memory products; and image sensor products. Micron Technology?s products are used in a range of electronic applications, including personal computers, workstations, network servers, mobile phones, flash memory cards, USB storage devices, digital still c ameras, MP3/4 players, and in automotive applications. It sells its products to original equipment manufacturers and retailers through internal sales force, independent sales representatives, and distributors, as well as through a Web-based customer direct sales channel. The company was founded in 1978 and is headquartered in Boise, Idaho.
Advisors' Opinion:- [By Jonas Elmerraji]
As impressive as T-Mobile's rally has been in 2013, it doesn't hold a candle to the momentum in shares of Micron Technology (MU) this year: since the calendar flipped over to January, Micron's share price has exploded by 207%. And with the way this stock is positioned right now, it's not too late to take the reins in Micron.
Micron is a computer memory maker that until recently was best known for manufacturing RAM for PCs. But the company has spent the last several years building its flash memory business, a switch that exposes Micron to a far more lucrative niche. Flash memory is a supply constrained business -- it's costly for newcomers to try to ramp up production, and the surge mobile device purchases has driven demand for NAND flash memory through the roof. That's helped Micron collect heftier prices and deeper margins for its efforts.
Most of Micron's flash memory customers are original equipment manufacturers, not consumers. Those OEM connections are a big advantage because they keep sales efforts minimal. Instead, the firm just needs to keep creating flash technology that device makers want. The increasing use of flash memory in enterprise settings (such as servers) is another big trend that's helped to propel Micron's share price in 2013.
- [By Paul Ausick]
We have tracked the key short interest changes as of September 30 in the following semiconductor leaders: Intel Corp. (NASDAQ: INTC), Advanced Micro Devices Inc. (NYSE: AMD), Micron Technology Inc. (NASDAQ: MU), SanDisk Corp. (NASDAQ: SNDK), Qualcomm Inc. (NASDAQ: QCOM), ARM Holdings PLC (NASDAQ: ARMH), Broadcom Corp. (NASDAQ: BRCM), Marvell Technology Group Ltd. (NASDAQ: MRVL), Nvidia Corp. (NASDAQ: NVDA), Texas Instruments Inc. (NASDAQ: TXN) and Applied Materials Inc. (NASDAQ: AMAT). We also chose to look at how the Market Vectors Semiconductor ETF (NYSEMKT: SMH) has held up.
Top 10 International Stocks To Invest In 2015: ChemoCentryx Inc (CCXI)
ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. The Company targets the chemokine system, a network of molecules, including chemokine ligands and their associated receptors, as well as related chemo-attractant receptors, all of which are known to drive inflammation. As of December 31, 2011, the Company had four drug candidates in clinical development. Its drug candidates include Traficet-EN (CCX282, GSK'786 or vercirnon), CCX140, CCX354, CCX168, CCX872, CCX507 and CCX662. The Company is also advancing several additional independent drug candidates through preclinical development. The Company�� wholly owned subsidiary is ChemoCentryx Limited.
The Company's drug candidate Traficet-EN (CCX282, GSK'786), is to control the inflammatory response underlying IBD by targeting the chemokine receptor known as CCR9. The Company has completed nine clinical trials with Traficet-EN in a total of 785 subjects, including five Phase I clinical trials (three in the United States and two in the United Kingdom), one thorough QT study in the United States (an assessment of cardiovascular safety which is required for regulatory approval), and three Phase II clinical trials (one in the Netherlands, the United Kingdom, and the United States, one in Finland and one (PROTECT-1) in Australia, Austria, Belgium, Brazil, Bulgaria, Canada, the Czech Republic, Denmark, France, Germany, Hungary, Israel, the Netherlands, Poland, South Africa, Sweden and the United Kingdom). As of December 31, 2011, the Company�� Traficet-EN drug candidate is in four pivotal Phase III clinical trials being conducted by its partner Glaxo Group Limited (GSK).
The Company's independent drug candidate CCX140, targets the chemokine receptor known as CCR2. CCX140 is a potent and selective antagonist of CCR2 that is found on subsets of monocytes and macrophages, which are cells of th! e immune system. In January 2011, the Company completed a 159-patient randomized Phase II clinical trial, conducted in Australia, the Czech Republic, Germany, Hungary and New Zealand, to assess the safety and tolerability of CCX140 in patients with type 2 diabetes. In addition, CCX140 demonstrated biological activity through a dose-dependent decrease in fasting plasma glucose.
CCX354 targets the chemokine receptor known as CCR1. Synovial fluid from the joints of rheumatoid arthritis (RA) patients contains high levels of activated CCR1 chemokine ligands. The Company completed two Phase I clinical trials in a total of 84 healthy subjects, conducted in Switzerland followed by a Phase I/II clinical trial in 24 patients with stable RA, conducted in Belgium and Romania, and a Phase II proof-of-concept clinical trial in 160 patients with moderate-to-severe RA, conducted in Belgium, the Czech Republic, Germany, Hungary, Poland, Romania and the Ukraine. GSK exercised its option to further develop and commercialize CCX354 in November 2011 and had an exclusive right to initiate a Phase II b clinical trial for CCX354 in RA.
CCX168 targets the chemo-attractant C5a receptor (C5aR), which binds to a biologically activated fragment of the complement protein known as C5. As of December 31, the Company completed a Phase I clinical trial for CCX168, conducted in Switzerland. The Company initiated a Phase II proof-of-concept clinical trial in AAV in the fourth quarter of 2011. Its CCX872 is an independent next generation CCR2 drug candidate for the treatment of metabolic diseases, its CCX507 is an independent drug candidate for the treatment of inflammatory bowel disease (IBD) and CCX662 is an independent drug candidate for the treatment of glioblastoma multiforme (GBM).
The Company competes with Abbott Laboratories, Amgen Inc, AstraZeneca plc, Biogen Idec Inc, Bayer AG, Elan Corporation plc, Glaxo Group Limited, Merck & Co Inc, Merck Serono, Takeda Pharmaceutical Co Ltd, Novartis AG! , Pfizer ! Inc, Reata Pharmaceuticals, Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd, Bristol-Myers Squibb, Incyte Corp and UCB Pharma.
Advisors' Opinion:- [By CRWE]
ChemoCentryx, Inc. (Nasdaq:CCXI), reported that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the BioCentury NewsMakers in the Biotech Industry Conference on Friday, September 7, 2012, at 9:30 a.m. Eastern Time at the Millennium Broadway Hotel & Conference Center in New York, NY.
Top 10 International Stocks To Invest In 2015: James Hardie Industries SE (JHX)
James Hardie Industries plc, together with its subsidiaries, manufactures and sells fiber cement products and systems for interior and exterior building construction applications primarily in the United States, Canada, Australia, New Zealand, the Philippines, and Europe. Its products principally include fiber cement interior linings, exterior siding products, and related accessories products. The company offers fiber cement products with various patterned profiles and surface finishes for a range of applications, including external siding and soffit lining, internal linings, facades, floor and tile underlay, lattice, fencing, decorative columns, flooring, and ceiling applications; and manufactures and sells fiber reinforced concrete pipes. Its products are used in various markets, such as new residential construction, which include single and multi-family housing; manufactured housing that comprise mobile and pre-fabricated homes; repair and remodeling; and various commerc ial and industrial applications, such as stores, warehouses, offices, hotels, motels, schools, libraries, museums, dormitories, hospitals, detention facilities, religious buildings, and gymnasiums. The company markets its fiber cement products and systems under various Hardie brand names, such as HardieBacker; and other brand names, such as Artisan Lap and Artisan Accent Trim by James Hardie, Cemplank and Prevail siding, Scyon, and Stria siding. The company sells its products directly, as well as through distributors, large home center retailers, small to medium size dealer outlets, and specialist distributors to dealers or lumber yards, consumers, builders, real estate developers, and distributor/hardware stores. James Hardie Industries plc was founded in 1888 and is headquartered in Dublin, the Republic of Ireland.
Advisors' Opinion:- [By Ian Sayson]
Exporters dropped. Samsung Electronics slipped 2.9 percent to 1.329 million won in Seoul. Canon Inc., the world�� biggest camera maker, fell 1.1 percent to 3,215 yen in Tokyo. James Hardie Industries SE (JHX), a building materials supplier that gets about 70 percent of sales from the U.S., tumbled 2.8 percent to A$9.37 in Sydney.
Top 10 International Stocks To Invest In 2015: IMS Health Holdings Inc (IMS)
IMS Health Holdings, Inc., incorporated on October 23, 2009, is a global information and technology services company providing clients in the healthcare industry with comprehensive solutions to measure and improve their performance. It has collections of healthcare information in the world, spanning sales, prescription and promotional data, medical claims, electronic medical records and social media. Its scaled and data set, containing over 10 petabytes of data, includes over 85% of the world�� prescriptions by sales revenue and approximately 400 million comprehensive, longitudinal, anonymous patient records. It serves healthcare organizations and decision makers around the world, spanning the breadth of life science companies, including pharmaceutical, biotechnology, consumer health and medical device manufacturers, as well as distributors, providers, payers, government agencies, policymakers, researchers and the financial community.
The Company uses healthcare-specific global information technology (IT) infrastructure to process data from over 45 billion healthcare transactions annually and to collect data from over 780,000 fragmented feeds globally, which it organize in a structured fashion using methodologies. Its intelligent cloud, IMS One opens its global IT infrastructure to its clients and provides the ability to perform business analytics in the cloud with large amounts of complex data. Its principal offerings include National information offerings; Sub-national information offerings; Commercial services; Real-World Evidence (RWE) solutions; Commercial technology solutions, and Clinical solutions.
The Company�� national offerings includes services in more than 70 countries that provide consistent country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment and promotional activity across multiple channels including retail, hospital and mail order. Its sub-national offerings includes services in more than 50 ! countries that provide a consistent measurement of sales or prescribing activity at the regional, zip code and individual prescriber level. The Company provides a set of strategic, analytic and support services to help the commercial operations of life sciences companies transform their commercial models. It integrate information from medical claims, prescriptions, electronic medical records, biomarkers and government statistics into anonymous, longitudinal patient journeys that provide detailed views of treatment patterns, disease progression, therapeutic switching and concomitant diseases and treatments.
The Company provides a range of hosted and cloud-based applications and associated implementation services. The applications, hosted on IMS One, support a range of commercial processes including multi-channel marketing, customer relationship management (CRM), performance management, incentive compensation, territory alignment, roster management and call planning. It helps life sciences companies design and execute clinical trials, and for payers and providers, it enables risk-sharing, pay-for-performance and population health management.
Advisors' Opinion:- [By Jayson Derrick]
After pricing its IPO at $20, shares of IMS Health (NYSE: IMS) began trading for the first time at $22.18, traded as high as $23.69 before closing the day at $23.00, up 15.00 percent.
- [By MONEYMORNING.COM]
Now then, as much as we like several companies in this space, we think investors would do well to take a close look at IMS Health Holdings Inc. (NYSE: IMS).
- [By Jake L'Ecuyer]
IMS Health Holdings (NYSE: IMS) shares were also up, gaining 17.40 percent to $23.45 in their debut on the NYSE.
Equities Trading DOWN
Shares of Halozyme Therapeutics (NASDAQ: HALO) were down 25.40 percent to $8.65 after the company announced the temporary halt of Phase 2 trial enrollment.
Top 10 International Stocks To Invest In 2015: MFS Special Value Trust (MFV)
MFS Special Value Trust (the fund) is a closed-end fund and maintains a portfolio that includes investments in fixed income and equity securities. During the fiscal year ended October 31, 2007, the MFS Special Value Trust provided a total return of 5.11%, at net asset value. The fund's investment objective is to seek high current income, but may also consider capital appreciation.
MFS Special Value Trust normally invests the fund's assets primarily in debt instruments. MFS Special Value Trust normally invests the fund's assets in United States Government securities, foreign government securities, mortgage backed and other asset-backed securities of United States and foreign issuers, corporate bonds of United States and foreign issuers, debt instruments of issuers located in emerging market countries, and equity securities. MFS Special Value Trust�� investment advisor is Massachusetts Financial Services Company.
Advisors' Opinion:- [By Dividends4Life]
According to a Gabelli Funds report, managed distribution policies offer several advantages, including:1. Lower difference between the fund�� market price and its NAV per share.2. Provides support during periods when the stock market is in a decline.3. Provides a measurable performance target for the investment adviser.Below are several high-yield funds from CEFA that have a managed distribution policy (yields as of December 16):Aberdeen Australia Eqty (IAF)- Distribution Yield: 10.4%- Income Yield: 3.46%Bexil Advisers LLC� (DNI)- Distribution Yield: 11.1%- Income Yield: 3.56%BlackRock En Capital&Inc (CII)- Distribution Yield: 8.78%- Income Yield: 2.34%Cornerstone Strat Value (CLM)- Distribution Yield: 18.77%- Income Yield: 1.83%Cornerstone Total Return (CRF)- Distribution Yield: 19.10%- Income Yield: 0.85%Delaware Inv Div & Inc (DDF)- Distribution Yield: 6.70%- Income Yield: 5.26%Gabelli Equity Trust (GAB)- Distribution Yield: 7.58%- Income Yield: 1.54%Gabelli Utility Trust (GUT)- Distribution Yield: 9.45%- Income Yield: 2.84%MFS Special Value Trust (MFV)- Distribution Yield: 9.60%- Income Yield: 5.73%Nuveen Tx-Adv TR Strat (JTA)- Distribution Yield: 6.70%- Income Yield: 3.12%TCW Strategic Income (TSI)- Distribution Yield: 10.54%- Income Yield: 7.88%Zweig Total Return (ZTR)- Distribution Yield: 7.27%- Income Yield: 1.95%As noted in the Gabelli report, a managed distribution policy may create confusion regarding the true current yield since the reported yield includes the return of capital portion. You can see the disparity above between the income yield and the distribution (reported) yield.If you are looking for a sustainable and growing dividend, you may want to consider some blue-chip dividend stocks such as these with a Free Cash Flow Payout less than 50%, 50+ years of consecutive dividend increases and a 2%+ yield:3M Co. (MMM) is a diversified global company provides enhanced product functionality in electronics, health care, industrial, consumer
No comments:
Post a Comment